Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd, dated September 10, 2024, reports a significant transaction involving the company's Executive Chairman. The filing serves to disclose a recent purchase of the company's ordinary shares on the NASDAQ.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific equity transaction rather than periodic financial performance.
Material Changes
- Share Purchase: Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone holds a beneficial interest, purchased 50,000 ordinary shares.
- Transaction Price: The shares were acquired at US$1.03 per share.
- Updated Ownership: Following this transaction, Mr. Cerrone's total shareholding stands at 9,851,570 shares, representing 29.12% of the issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, operational outlook, or specific risk factors. The document strictly reports the share acquisition and notes that the attached news announcement is furnished but not deemed "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the exact beneficial interest structure of Gabriele Cerrone in Panetta Partners Limited.
- Confirm the total issued share capital to validate the 29.12% ownership calculation.
- Review the attached Exhibit 99.1 (News Announcement) for any additional context regarding the transaction.
- Check for any subsequent filings regarding further insider trading or changes in beneficial ownership.